PE-22-28 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Superior TREK-1 inhibition (IC50: 0.12 nM vs 40-60 nM for native spadin) with rapid antidepressant effects in rodent stress models. 4-day onset compared to weeks for conventional antidepressants. No human clinical trials. PE-22-28 is not fda-approved. investigational research peptide only.
What Does the Research Say About PE-22-28?
Superior TREK-1 inhibition (IC50: 0.12 nM vs 40-60 nM for native spadin) with rapid antidepressant effects in rodent stress models. 4-day onset compared to weeks for conventional antidepressants. No human clinical trials.
PE-22-28 (PE-22-28 (spadin analog, TREK-1 inhibitor)) is a Ion channel inhibitor peptide. Research interest has focused on its potential effects on rapid antidepressant effects (4 days vs 4-6 weeks for SSRIs), hippocampal neurogenesis, enhanced synaptogenesis.
What Is the Evidence for PE-22-28's Mechanism?
Antagonizes TREK-1 (TWIK-related potassium channel), blocking potassium conductance to depolarize neurons and increase membrane excitability. Enhances serotonergic neuron firing and elevates monoamine neurotransmission, producing rapid antidepressant effects within 4 days by stimulating hippocampal neurogenesis.
These pathways have been identified through in vitro studies, animal models, and where available, human trials.
Are There Human Clinical Trials for PE-22-28?
Superior TREK-1 inhibition (IC50: 0.12 nM vs 40-60 nM for native spadin) with rapid antidepressant effects in rodent stress models. 4-day onset compared to weeks for conventional antidepressants. No human clinical trials.
The gap between preclinical promise and clinical validation remains the biggest challenge in peptide research. However, PE-22-28 has shown encouraging results.
What Does the Safety Research Show?
Minimal toxicity in animal models. Potential hypertension from enhanced monoamine activity. Human safety unknown. GABAergic disruption possible.
PE-22-28 is not fda-approved. investigational research peptide only.
What Makes PE-22-28 Unique in Research?
Demonstrates antidepressant onset in 4 days versus 4-6 weeks for conventional medications — if human efficacy confirms, this would be the fastest-acting peptide antidepressant.
This differentiator is important because it means PE-22-28 fills a role that other compounds in its class may not fully replicate.
Bottom Line on PE-22-28 Research
The evidence base for PE-22-28 is growing. Key research areas include rapid antidepressant effects (4 days vs 4-6 weeks for SSRIs), hippocampal neurogenesis, enhanced synaptogenesis.
Stay current with PubMed searches for PE-22-28 for the latest publications.
Complete Guide
PE-22-28 : Benefits, Dosage, Side Effects & Research
Related Reading
- PE-22-28 Dosage Guide
- PE-22-28 Benefits
- PE-22-28 Side Effects
- PE-22-28 Stacking Guide
- PE-22-28 Cycle Guide
Calculate Your PE-22-28 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for PE-22-28.
Open Calculator →Research-Grade Sourcing
If you're going to research PE-22-28, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is PE-22-28?
PE-22-28 (PE-22-28 (spadin analog, TREK-1 inhibitor)) is a Ion channel inhibitor peptide. Synthetic shortened analog of spadin with enhanced TREK-1 potassium channel specificity and brain stability. It is researched for rapid antidepressant effects (4 days vs 4-6 weeks for SSRIs), hippocampal neurogenesis, enhanced synaptogenesis.
What is the recommended PE-22-28 dosage?
Common dosages: 100-500 mcg daily administered once daily via subcutaneous injection (proposed). Cycle length: 4-8 weeks. Half-life: 14-23 hours in rodents. Use our peptide calculator for exact reconstitution math.
What are the side effects of PE-22-28?
Minimal toxicity in animal models. Potential hypertension from enhanced monoamine activity. Human safety unknown. GABAergic disruption possible.
Is PE-22-28 safe?
PE-22-28 has shown a preliminary safety profile in research. Not FDA-approved. Investigational research peptide only. All research should follow appropriate safety protocols.